...
首页> 外文期刊>European review for medical and pharmacological sciences. >The treatment of Kaposi’s sarcoma: present and future options, a review of the literature
【24h】

The treatment of Kaposi’s sarcoma: present and future options, a review of the literature

机译:Kaposi的肉瘤治疗:现在和未来的选择,对文献进行了综述

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Kaposi’s Sarcoma (KS) is an angiogenic tumor involving skin, mucosa and splanchnic organs. It is caused by Human Herpes Virus 8 (HHV8), when in the presence of other cofactors, such as an immune dysregulation. KS is particularly frequent in HIV-infected individuals. The major goals of treatment are to prevent disease progression, to reduce tumor and edema, to avoid organ compromise, and to relieve psychological stress. The importance and the high cancer risk offered by this co-infection, together with the spread of both these viruses, and the fact that angiogenesis is such an important characteristic of KS led to a lively interest in finding a definitive therapy. Most of the ongoing studies are focused on finding an application of old drugs in KS. Unfortunately, given the number of studies with different targets, it seems we are still far from completely understanding this disease and obtaining a “cure” which could be effective and safe for everyone. Further studies will hopefully offer new and definitive solutions.
机译:Kaposi的Sarcoma(KS)是一种诱导血管生成肿瘤,涉及皮肤,粘膜和脾气。它是由人疱疹病毒8(HHV8)引起的,当在其他辅助因子的存在下,例如免疫失调。 Ks在艾滋病毒感染的个体中特别频繁。治疗的主要目标是预防疾病进展,以减少肿瘤和水肿,以避免器官妥协,并缓解心理压力。这种共感染的重要性和高癌症风险与这些病毒的传播以及血管生成是血管生成的蔓延,以及KS的这种重要特征导致了寻找最终疗法的热烈兴趣。大多数正在进行的研究都集中在ks中的旧药物的应用。遗憾的是,鉴于不同目标的研究数量,似乎我们仍然远远彻底了解这种疾病并获得“治愈”,这可能对每个人都有有效和安全。进一步的研究希望提供新的和明确的解决方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号